Filing summary
Entity discrepancy: The request identifies Fennec Pharmaceuticals Inc., but the supplied Form 10-Q is for Adherex Technologies Inc. This summary reflects the filing provided, not a Fennec filing.
Business context and reporting period
Adherex was a development-stage biopharmaceutical company focused on cancer therapeutics. This unaudited Form 10-Q covers the quarter and nine months ended September 30, 2011; amounts below are U.S. dollars in thousands unless stated otherwise. The company had no product revenue. It completed a 1-for-18 reverse stock split effective August 25, 2011.
Key financial metrics
| Metric | Period/value |
|---|---|
| Revenue | $0 for Q3 and the first nine months of 2011 |
| Operating expenses | Q3: $944; nine months: $2,536 |
| Net income/(loss) | Q3: $(3,144); nine months: $1,176 |
| Derivative gain/(loss) | Q3: $(2,221); nine months: $3,683; noncash fair-value changes were a major influence on reported earnings |
| Operating cash flow | $(636) in Q3; $(2,459) for nine months |
| Cash and cash equivalents | $6,174 at September 30, 2011, versus $5,947 at December 31, 2010; included $5,918 in money market investments |
| Liquidity and liabilities | Working capital was $5,795, calculated excluding derivative warrant liabilities. Total liabilities were $9,941, including a $9,465 derivative liability; other current liabilities were $476. |
| Debt and equity | No material debt balance is identified in the filing. Stockholders’ deficiency was $3,670; accumulated development-stage deficit was $108,886. |
| Contractual obligations | $947 total, including $219 due within one year, primarily clinical-service, database-service, and drug-purchase commitments. |
Material changes versus comparable periods
- Q3 net loss of $3,144 compared with net income of $1,694 in Q3 2010, principally reflecting a $2,221 derivative loss versus a $2,570 derivative gain in the prior-year quarter.
- Q3 operating expenses were nearly unchanged year over year ($944 versus $917). Research and development expense rose to $439 from $110 as the eniluracil Phase II trial began recruiting; general and administrative expense fell to $505 from $807, mainly due to lower stock-based compensation.
- Nine-month net income of $1,176 compared with a $1,240 loss in 2010. The result included a $3,683 derivative gain; operating expenses declined to $2,536 from $3,788, primarily due to lower stock-based compensation, partly offset by increased trial spending.
- Cash increased by $227 from year-end, reflecting the March 2011 rights offering proceeds, partly offset by operating cash use. The rights offering generated approximately $2.6 million net proceeds.
Outlook, risks, contingencies, and unusual items
- Going concern: Management stated that substantial doubt existed about the company’s ability to meet obligations as they come due. It expected to need additional financing through equity, debt, collaborations, licensing, or other sources; failure to obtain funding could require delays, reductions, or cessation of activities.
- Clinical programs: The eniluracil Phase II trial was open for recruitment in Russia and the United States, with its first patient enrolled April 27, 2011. Management expected enrollment of approximately 140 patients to take 12–14 months from trial commencement. STS Phase III trials were being conducted by SIOPEL and the Children’s Oncology Group; the company noted prior activation and enrollment delays and depended on these collaborators.
- Development and revenue outlook: The company did not expect significant revenue until products received regulatory approval or collaborations generated payments. Eniluracil had previously failed to produce positive Phase III results under GlaxoSmithKline; further development remained uncertain. The company lacked the financial and human resources to complete Phase III trials independently.
- Accounting and share structure: Canadian-dollar-denominated warrants were carried as derivative liabilities and remeasured using a Black-Scholes model, creating potentially volatile noncash earnings. The reverse split reduced common shares outstanding from approximately 452.8 million to 25.2 million.
- Controls and legal matters: Disclosure controls were deemed ineffective due to material weaknesses involving segregation of accounting duties and insufficient technical accounting personnel. The filing reported no legal proceedings.
Important facts for investors to verify
- Confirm the filing issuer: the supplied report is Adherex Technologies Inc., not Fennec Pharmaceuticals Inc.
- Assess cash runway and the timing, availability, and potential dilution or terms of required future financing.
- Track eniluracil Phase II enrollment, trial costs, and any reported results; verify collaborator progress and enrollment in STS trials.
- Review derivative-liability valuation assumptions and distinguish noncash fair-value gains or losses from operating performance and cash use.
- Monitor remediation of the disclosed material weaknesses and the company’s ability to meet exchange listing requirements.